Last updated: September 23, 2026
Methscopolamine bromide is a mature oral anticholinergic with limited commercial relevance. Its U.S. market has contracted because its historical peptic-ulcer indication was displaced by proton-pump inhibitors and H2-receptor antagonists, while newer anticholinergics compete for gastrointestinal and secretory-disorder use. The product has no meaningful remaining exclusivity barrier, no identified active U.S. patent estate of commercial significance, and no public product-level revenue disclosure. Current commercial value is likely limited to small-volume legacy prescriptions, institutional demand, and occasional generic availability.
What is methscopolamine bromide used for?
Methscopolamine bromide is a quaternary ammonium antimuscarinic drug. It reduces gastrointestinal secretions and smooth-muscle activity by inhibiting muscarinic acetylcholine receptors.
The historical U.S. label positioned methscopolamine bromide as an adjunct to peptic-ulcer treatment rather than as a disease-modifying therapy. The labeled products included Pamine and Pamine Forte tablets in 2.5-mg and 5-mg strengths. The label also identified use in gastrointestinal disorders involving excessive secretion or spasm, subject to the limitations of anticholinergic therapy.[1]
Its pharmacologic profile creates several commercial disadvantages:
- Limited central nervous system penetration because the molecule is quaternary.
- Anticholinergic adverse effects, including dry mouth, blurred vision, constipation, urinary retention and tachycardia.
- Contraindications and warnings involving glaucoma, obstructive gastrointestinal conditions, urinary retention and certain cardiac conditions.
- No role in Helicobacter pylori eradication.
- No disease-modifying effect on ulcer healing comparable to modern acid-suppressive therapy.
How has the methscopolamine bromide market evolved?
The market moved through three commercial phases.
| Period |
Market condition |
Commercial effect |
| 1950s-1970s |
Anticholinergics were used as adjuncts in peptic-ulcer management |
Established legacy demand |
| 1980s-1990s |
H2 blockers and proton-pump inhibitors became standard ulcer treatments |
Rapid erosion of anticholinergic demand |
| 2000s-present |
Methscopolamine remained a niche legacy product with limited generic activity |
Low-volume, low-investment market |
The principal structural change was therapeutic substitution. Cimetidine, ranitidine, famotidine and later omeprazole-class products offered more direct acid suppression and stronger clinical positioning. Modern guidelines for peptic-ulcer disease emphasize acid suppression, Helicobacter pylori treatment and nonsteroidal anti-inflammatory drug management rather than routine use of gastrointestinal anticholinergics.[2][3]
Methscopolamine therefore lost its historical market before generic competition became the dominant issue. Generic entry did not create the decline. It followed a decline caused by obsolescence of the principal treatment setting.
What is the FDA regulatory status of methscopolamine bromide?
Methscopolamine bromide has an established U.S. regulatory history, but current commercial status is fragmented.
The historical branded products were Pamine and Pamine Forte. Public drug-label repositories continue to identify methscopolamine bromide tablet labeling, although product availability can vary by manufacturer, wholesaler and national drug database.[1] Product discontinuation in commercial databases does not necessarily establish that the FDA withdrew approval for safety or efficacy reasons. FDA records distinguish between discontinued marketing, withdrawn approval and discontinued labeling.
The relevant regulatory characteristics are:
| Regulatory issue |
Assessment |
| Active ingredient |
Methscopolamine bromide |
| Dosage form |
Immediate-release oral tablet |
| Historical strengths |
2.5 mg and 5 mg |
| U.S. pathway |
Legacy prescription-drug approval and generic-equivalent pathways |
| Biologic status |
Not a biologic |
| Biosimilar exposure |
None |
| Pediatric exclusivity |
No current commercial relevance identified |
| Orphan exclusivity |
None identified |
| New chemical entity exclusivity |
Expired decades ago |
| Current market |
Limited and inconsistent relative to mainstream gastrointestinal drugs |
FDA labeling is commercially important because methscopolamine is not positioned as a modern first-line gastrointestinal product. The prescribing information contains extensive anticholinergic warnings and a narrow risk-benefit profile.[1]
When did methscopolamine bromide lose exclusivity?
Methscopolamine bromide lost meaningful exclusivity decades ago. The active ingredient was introduced during the mid-20th century, and any original composition-of-matter, formulation or regulatory exclusivity has long expired.
The commercial exclusivity timeline is therefore:
| Exclusivity category |
Status |
| Original compound patent |
Expired |
| Original product patent |
Expired or commercially irrelevant |
| FDA new-drug exclusivity |
Expired |
| Pediatric exclusivity |
No active period identified |
| Orphan exclusivity |
None identified |
| Formulation exclusivity |
No active commercially meaningful period identified |
| Method-of-use exclusivity |
No active commercially meaningful period identified |
| Data exclusivity |
Expired |
The key commercial question is not when a patent expires. It is whether a manufacturer can supply the product economically despite low demand, limited manufacturing scale and weak reimbursement leverage.
What patents protect methscopolamine bromide?
No active U.S. patent estate of material commercial significance has been identified for the legacy methscopolamine bromide tablet market.
The FDA Orange Book is the primary source for patents listed against approved small-molecule drug products. Methscopolamine bromide does not present the profile of a product protected by current composition, formulation or method-of-use patents. The relevant patent barriers are historical rather than operative.[4]
Are there formulation patents for methscopolamine bromide?
No commercially significant contemporary formulation patent position is apparent for the conventional immediate-release tablet. The product is a relatively simple oral dosage form, and the historical formulation would generally be vulnerable to ordinary generic development.
Potential technical barriers are limited to:
- Sourcing and specification of the active pharmaceutical ingredient.
- Control of tablet potency and content uniformity.
- Stability and packaging.
- Small-scale manufacturing economics.
- Regulatory documentation for an older, low-demand product.
These are manufacturing and market-access barriers, not patent barriers.
Are there method-of-use patents for methscopolamine bromide?
No active method-of-use patent position of commercial importance is apparent for the historical peptic-ulcer or gastrointestinal-spasm indications. Those uses are longstanding and would not normally support a new enforceable exclusivity position without a newly patented indication, dosing regimen or patient population.
How many patents cover methscopolamine bromide?
For practical U.S. generic-entry analysis, the number of active, commercially material Orange Book patents is effectively zero.
This does not mean that no historical patent document ever referenced methscopolamine, scopolamine derivatives or anticholinergic formulations. It means that the current product opportunity is not constrained by an identified enforceable patent estate comparable to a modern branded drug.
The distinction matters:
- Historical patent references may exist.
- Expired patents do not block approval or launch.
- Unlisted patents generally do not create Hatch-Waxman Orange Book certification obligations.
- No current patent portfolio appears to support premium pricing or settlement leverage.
Are there Paragraph IV challenges to methscopolamine bromide?
No prominent, publicly reported Paragraph IV litigation campaign is associated with methscopolamine bromide.
That outcome is commercially logical. Paragraph IV litigation is most common where a branded product has substantial revenue, a valuable remaining market and patents capable of delaying generic entry. Methscopolamine bromide lacks those conditions.
Potential generic applicants would have little incentive to challenge patents where:
- The market is small.
- The active ingredient is old.
- The branded product has limited or inconsistent availability.
- No meaningful patent barrier is visible.
- The expected litigation prize is low.
The absence of reported litigation should not be interpreted as evidence of strong brand protection. It reflects weak economic incentives to litigate.
What patent litigation affects methscopolamine bromide?
No material current U.S. patent litigation involving methscopolamine bromide has been identified in the public drug-patent record.
There is no known litigation pattern involving:
- Hatch-Waxman infringement claims;
- Paragraph IV certifications against an active brand;
- Patent settlement agreements;
- Authorized-generic launch restrictions;
- Formulation or manufacturing patent enforcement;
- Patent-transfer or licensing disputes tied to the product.
The litigation risk is therefore low. Product availability and regulatory status present greater operational risks than patent enforcement.
Which companies manufacture or market methscopolamine bromide?
The product has historically been associated with Pamine and Pamine Forte, with marketing and labeling responsibility changing over time. Generic and legacy-label availability has also varied among pharmaceutical manufacturers and distributors.
The market is not controlled by a large, clearly disclosed innovator franchise. It is better characterized as a fragmented legacy market in which:
- Branded recognition is weak.
- Generic supply may be intermittent.
- Wholesale distribution may determine practical availability.
- Manufacturer participation can change without a major strategic announcement.
- Product-level sales are generally not reported by public companies.
No major contemporary licensing transaction centered on methscopolamine bromide has been publicly established. The product does not appear to be a meaningful driver of the strategy or revenue disclosures of major pharmaceutical companies.
What is the financial trajectory for methscopolamine bromide?
The financial trajectory is structurally negative, with possible stabilization at a very small niche level rather than a return to growth.
Revenue profile
Public company filings do not generally disclose methscopolamine bromide revenue as a separate line item. The product is usually buried within broader categories such as generic pharmaceuticals, legacy products or other prescription products.
A defensible financial assessment is therefore qualitative:
| Financial metric |
Assessment |
| Historical peak relevance |
Legacy gastrointestinal adjunct market |
| Current revenue scale |
Small and not separately disclosed |
| Growth rate |
Structurally declining or stagnant |
| Pricing power |
Weak |
| Gross-margin potential |
Sensitive to manufacturing scale |
| Reimbursement leverage |
Limited |
| Sales and marketing investment |
Unlikely to be material |
| Business-development value |
Low unless bundled with a broader legacy portfolio |
| Revenue visibility |
Poor because supply and listing status can change |
Main drivers of further decline
The principal revenue pressures are:
- Continued dominance of proton-pump inhibitors and H2 blockers.
- Reduced use of anticholinergic adjuncts in ulcer care.
- Safety concerns in older adults and patients with urinary or gastrointestinal obstruction.
- Low prescriber familiarity.
- Limited product availability.
- Generic price compression.
- Low incentive to maintain multiple suppliers.
- Weak consumer demand because the product is prescription-only and niche.
Factors that could support residual demand
Residual demand may persist where clinicians seek an oral anticholinergic for a narrow gastrointestinal indication, where a patient has historical treatment continuity, or where alternatives are unavailable or poorly tolerated. That demand is unlikely to support substantial commercial expansion.
What generic entry risks exist for methscopolamine bromide?
Generic-entry risk is high in legal terms but modest in market-disruption terms.
Because the product has no meaningful remaining exclusivity, a qualified manufacturer could generally pursue an abbreviated approval strategy if a reference product and applicable regulatory pathway are available. The more important barriers are commercial:
- Small addressable volume.
- Uncertain reference-product status.
- Difficulty forecasting demand.
- Potential active-ingredient sourcing constraints.
- Low expected return on regulatory investment.
- Risk that wholesalers will not maintain inventory.
- Price erosion after additional entrants.
A new generic entrant would probably seek a low-cost, low-overhead strategy rather than invest in sales promotion or differentiated formulation.
How does methscopolamine bromide compare with competing drugs?
| Drug or class |
Primary role |
Market position |
Competitive effect on methscopolamine |
| Omeprazole and other PPIs |
Acid suppression and ulcer treatment |
Mainstream and guideline-supported |
Strong substitution |
| Famotidine and other H2 blockers |
Acid suppression |
Established alternative |
Strong substitution |
| Hyoscyamine |
Antispasmodic and anticholinergic use |
Legacy niche |
Direct class competition |
| Glycopyrrolate |
Anticholinergic use, including secretion control |
More prominent in selected indications |
Competes in specialist settings |
| Atropine/scopolamine products |
Anticholinergic effects |
Indication-specific |
Partial substitution |
| Sucralfate |
Mucosal protection |
Narrower legacy role |
Historical ulcer-market competitor |
Methscopolamine has no clear clinical advantage that would support premium pricing against modern acid suppression or against more familiar anticholinergics.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more relevant than intellectual-property barriers.
The active ingredient is old, but commercial supply can still be vulnerable to:
- Limited API suppliers.
- Small batch sizes.
- Low forecast accuracy.
- Discontinuation decisions by contract manufacturers.
- Packaging and stability requirements.
- Low inventory turns.
- Regulatory maintenance costs that exceed product contribution.
For a legacy product, the fixed cost of maintaining an approved product can exceed the incremental cost of manufacturing individual tablets. That dynamic can produce shortages or market exits even where no patent blocks competition.
What is the generic launch outlook?
The most likely launch scenarios are:
| Scenario |
Probability assessment |
Market effect |
| No new entrant |
Most commercially plausible |
Continued niche supply and intermittent availability |
| One low-cost generic entrant |
Plausible |
Improved availability, rapid price pressure |
| Multiple generic entrants |
Less likely |
Severe price compression and possible supplier exits |
| Branded relaunch |
Unlikely |
Requires a new clinical or commercial rationale |
| Reformulated product with new patenting |
Unlikely |
Limited market size does not justify development cost |
A generic launch would not materially expand the therapeutic market. It would mainly redistribute a small existing volume among suppliers.
What is the geographic coverage of the methscopolamine bromide market?
The strongest historical commercial footprint has been in the United States, where Pamine and Pamine Forte were recognized prescription products. International availability is less clear and may depend on local registrations, national formularies and country-specific anticholinergic use.
Geographic expansion is unlikely to be attractive because:
- The clinical indication is mature.
- Local registration costs would be high relative to expected volume.
- Modern ulcer treatment has displaced the historical use.
- Generic pricing limits the return on international launches.
- Many jurisdictions apply heightened caution to systemic anticholinergic drugs.
The commercial opportunity is therefore predominantly maintenance-oriented rather than expansion-oriented.
What is the investment and licensing outlook?
Methscopolamine bromide has low standalone licensing value. A transaction would be more likely to involve a bundle of mature products, a contract-manufacturing portfolio or a broader gastrointestinal franchise than the molecule alone.
Potential value is concentrated in:
- Existing regulatory approvals.
- Manufacturing continuity.
- Established wholesaler relationships.
- Inventory and supply-chain capability.
- Portfolio bundling with other legacy prescription products.
The asset is unlikely to attract investment based on patent life, clinical differentiation or high-growth revenue potential.
Key Takeaways
- Methscopolamine bromide is a mature oral anticholinergic with a declining or stagnant niche market.
- Its historical peptic-ulcer role was displaced by proton-pump inhibitors, H2 blockers and Helicobacter pylori treatment.
- Original patent and regulatory exclusivities expired decades ago.
- No active U.S. patent estate of material commercial significance is apparent.
- No prominent Paragraph IV litigation, patent settlement or current patent dispute is associated with the product.
- Biosimilar risk is irrelevant because methscopolamine bromide is a small-molecule drug.
- Public companies do not separately disclose meaningful product revenue for methscopolamine bromide.
- Supply continuity, API sourcing and manufacturing economics are greater risks than patent enforcement.
- A new generic entrant could face no major legal barrier but would confront a small, low-margin market.
- Standalone licensing or investment value is low unless the product is acquired as part of a broader legacy portfolio.
FAQs
Is methscopolamine bromide still commercially available?
Availability is limited and can vary by manufacturer, wholesaler and pharmacy. Historical brands include Pamine and Pamine Forte, while generic availability has been inconsistent.
Is methscopolamine bromide the same as scopolamine?
No. Both are antimuscarinic compounds, but methscopolamine bromide is a quaternary ammonium derivative with different pharmacokinetic characteristics from scopolamine.
Can a generic company launch methscopolamine bromide without a patent challenge?
Potentially. Because no meaningful active patent barrier is apparent, the main obstacles are identifying an applicable reference product, satisfying FDA requirements and achieving sufficient commercial scale.
Does methscopolamine bromide have orphan-drug value?
No orphan-drug commercial position is identified. Its historical indications are broad gastrointestinal uses rather than a narrowly defined rare disease.
Could methscopolamine bromide become a growth product through reformulation?
A reformulation could theoretically create a new development opportunity, but the small market, anticholinergic safety profile and strong therapeutic substitution make a commercially attractive reformulation unlikely.
References
-
DailyMed. (n.d.). Methscopolamine bromide tablet prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Peptic ulcers and their treatment. U.S. Department of Health and Human Services. https://www.niddk.nih.gov/
-
American College of Gastroenterology. (2017). ACG clinical guideline: Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology, 112(2), 212-239. https://doi.org/10.1038/ajg.2016.563
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
